Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Eagle Asset Management Inc.

Eagle Asset Management Inc. trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 18.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 154,652 shares of the biotechnology company's stock after selling 34,215 shares during the period. Eagle Asset Management Inc. owned about 0.24% of Blueprint Medicines worth $15,594,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BPMC. Charles Schwab Investment Management Inc. lifted its holdings in Blueprint Medicines by 9.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 597,232 shares of the biotechnology company's stock worth $55,244,000 after buying an additional 50,736 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Blueprint Medicines by 48.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company's stock worth $23,332,000 after purchasing an additional 82,693 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Blueprint Medicines during the third quarter worth approximately $1,712,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in Blueprint Medicines in the third quarter valued at approximately $6,465,000. Finally, Advisors Asset Management Inc. increased its stake in Blueprint Medicines by 17.6% in the third quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company's stock valued at $467,000 after purchasing an additional 756 shares during the last quarter.

Blueprint Medicines Price Performance

Blueprint Medicines stock traded down $2.47 during mid-day trading on Friday, reaching $94.15. The company had a trading volume of 663,581 shares, compared to its average volume of 746,414. The stock's 50-day simple moving average is $90.36 and its 200-day simple moving average is $98.53. The company has a market capitalization of $5.98 billion, a P/E ratio of -44.62 and a beta of 0.59. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. Blueprint Medicines Co. has a 1 year low of $66.61 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to analysts' expectations of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. Blueprint Medicines's revenue was up 126.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.20) earnings per share. On average, equities analysts predict that Blueprint Medicines Co. will post -3.68 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BPMC. JMP Securities restated a "market outperform" rating and issued a $125.00 target price on shares of Blueprint Medicines in a report on Monday, November 18th. UBS Group began coverage on Blueprint Medicines in a report on Thursday, October 24th. They set a "neutral" rating and a $88.00 price objective on the stock. Wells Fargo & Company decreased their target price on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating for the company in a research report on Thursday, October 31st. Robert W. Baird increased their price objective on Blueprint Medicines from $112.00 to $127.00 and gave the company an "outperform" rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. assumed coverage on shares of Blueprint Medicines in a report on Thursday, November 14th. They issued an "overweight" rating and a $126.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $122.11.

Insider Buying and Selling

In related news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the transaction, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. The trade was a 5.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.